References
Chatterjee K, Zhang J, Honbo N, & Karliner JS (2010). Doxorubicin
cardiomyopathy. Cardiology 115: 155-162.
D’Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, & Senni M
(2017). Neprilysin inhibition in heart failure: mechanisms and
substrates beyond modulating natriuretic peptides. European journal of
heart failure 19: 710-717.
Elshabrawy HA, Essani AE, Szekanecz Z, Fox DA, & Shahrara S (2017).
TLRs, future potential therapeutic targets for RA. Autoimmun Rev
16: 103-113.
Henrick BM, Yao XD, Taha AY, German JB, & Rosenthal KL (2016). Insights
into Soluble Toll-Like Receptor 2 as a Downregulator of Virally Induced
Inflammation. Front Immunol 7: 291.
Hu C, Zhang X, Zhang N, Wei WY, Li LL, Ma ZG, et al. (2020).
Osteocrin attenuates inflammation, oxidative stress, apoptosis, and
cardiac dysfunction in doxorubicin-induced cardiotoxicity. Clinical and
translational medicine.
Hubers SA, & Brown NJ (2016). Combined Angiotensin Receptor Antagonism
and Neprilysin Inhibition. Circulation 133: 1115-1124.
Jacquet A, & Robinson C (2020). Proteolytic, lipidergic and
polysaccharide molecular recognition shape innate responses to house
dust mite allergens. Allergy 75: 33-53.
Jing W, Vaziri ND, Nunes A, Suematsu Y, Farzaneh T, Khazaeli M, et
al. (2017). LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress,
inflammation, fibrosis and improves renal function beyond angiotensin
receptor blockade in CKD. American journal of translational research
9: 5473-5484.
Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, et
al. (2010). TIMP2 deficiency accelerates adverse post-myocardial
infarction remodeling because of enhanced MT1-MMP activity despite lack
of MMP2 activation. Circ Res 106: 796-808.
Li B, Xia Y, & Hu B (2020). Infection and atherosclerosis:
TLR-dependent pathways. Cellular and molecular life sciences : CMLS
77: 2751-2769.
Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, et
al. (2018). Phosphoinositide 3-Kinase Gamma Inhibition Protects From
Anthracycline Cardiotoxicity and Reduces Tumor Growth. Circulation
138: 696-711.
Li X, Zhu Q, Wang Q, Zhang Q, Zheng Y, Wang L, et al. (2020).
Protection of Sacubitril/Valsartan against Pathological Cardiac
Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure
Overload in Mice. Cardiovascular drugs and therapy.
Liang S, Xinyong C, Hongmin Z, Jing W, Lang H, & Ping Z (2018). TLR2
and TLR3 expression as a biomarker for the risk of doxorubicin-induced
heart failure. Toxicology letters 295: 205-211.
Lilley E, Stanford SC, Kendall DE, Alexander SPH, Cirino G, Docherty
JR, et al. (2020). ARRIVE 2.0 and the British Journal of
Pharmacology: Updated guidance for 2020. British journal of pharmacology
177: 3611-3616.
Lillyblad MP (2015). Dual Angiotensin Receptor and Neprilysin Inhibition
with Sacubitril/Valsartan in Chronic Systolic Heart Failure:
Understanding the New PARADIGM. The Annals of pharmacotherapy
49: 1237-1251.
Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, Ambrosy AP,
et al. (2020). Sacubitril/Valsartan in Advanced Heart Failure With
Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC
Heart failure.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR,
et al. (2014). Angiotensin-neprilysin inhibition versus enalapril in
heart failure. The New England journal of medicine 371:993-1004.
Nozaki N, Shishido T, Takeishi Y, & Kubota I (2004). Modulation of
doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout
mice. Circulation 110: 2869-2874.
Oatmen KE, Zile MR, Burnett JC, Jr., & Spinale FG (2018). Bioactive
Signaling in Next-Generation Pharmacotherapies for Heart Failure: A
Review. JAMA cardiology 3: 1232-1243.
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M,
et al. (2020). The ARRIVE guidelines 2.0: updated guidelines for
reporting animal research. The Journal of physiology.
Pop-Moldovan AL, Trofenciuc NM, Darabantiu DA, Precup C, Branea H,
Christodorescu R, et al. (2017). Customized laboratory TLR4 and
TLR2 detection method from peripheral human blood for early detection of
doxorubicin-induced cardiotoxicity. Cancer gene therapy 24:203-207.
Riad A, Bien S, Gratz M, Escher F, Westermann D, Heimesaat MM, et
al. (2008). Toll-like receptor-4 deficiency attenuates
doxorubicin-induced cardiomyopathy in mice. European journal of heart
failure 10: 233-243.
Suematsu Y, Miura S, Goto M, Matsuo Y, Arimura T, Kuwano T, et
al. (2016). LCZ696, an angiotensin receptor-neprilysin inhibitor,
improves cardiac function with the attenuation of fibrosis in heart
failure with reduced ejection fraction in streptozotocin-induced
diabetic mice. European journal of heart failure 18: 386-393.
Tacar O, Sriamornsak P, & Dass CR (2013). Doxorubicin: an update on
anticancer molecular action, toxicity and novel drug delivery systems.
The Journal of pharmacy and pharmacology 65: 157-170.
Turner AJ, Isaac RE, & Coates D (2001). The neprilysin (NEP) family of
zinc metalloendopeptidases: genomics and function. BioEssays : news and
reviews in molecular, cellular and developmental biology 23:261-269.
Vejpongsa P, & Yeh ET (2014). Prevention of anthracycline-induced
cardiotoxicity: challenges and opportunities. Journal of the American
College of Cardiology 64: 938-945.
von Lueder TG, Wang BH, Kompa AR, Huang L, Webb R, Jordaan P, et
al. (2015). Angiotensin receptor neprilysin inhibitor LCZ696 attenuates
cardiac remodeling and dysfunction after myocardial infarction by
reducing cardiac fibrosis and hypertrophy. Circulation Heart failure
8: 71-78.
Xia Y, Chen Z, Chen A, Fu M, Dong Z, Hu K, et al. (2017). LCZ696
improves cardiac function via alleviating Drp1-mediated mitochondrial
dysfunction in mice with doxorubicin-induced dilated cardiomyopathy.
Journal of molecular and cellular cardiology 108: 138-148.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM,
et al. (2016). 2016 ACC/AHA/HFSA Focused Update on New Pharmacological
Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for
the Management of Heart Failure: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines and the Heart Failure Society of America. Journal of the
American College of Cardiology 68: 1476-1488.
Yang HL, Hsieh PL, Hung CH, Cheng HC, Chou WC, Chu PM, et al.(2020). Early Moderate Intensity Aerobic Exercise Intervention Prevents
Doxorubicin-Caused Cardiac Dysfunction Through Inhibition of Cardiac
Fibrosis and Inflammation. Cancers 12.
Table Biometric and echocardiographic parameters of the
experimental mice.